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Human monocytes can be classified into at least two distinct groups, classical and non-classical based on CD14 and CD16 expression. These monocyte subsets express chemokine receptors CCR2 and CX3CR1, respectively, which direct specific tissue migration toward sites of selective chemokine secretion during infection (Ziegler-Heitbrock et al., 2010 (Balboa et al., 2011; Buckner et al., 2011; Chimma et al., 2009; Lentz et al., 2011; Williams et al., 2012; Ziegler-Heitbrock et al., 2010) . Transcriptome profiling of this group has characterised these as antigen presenting cells with unique proinflammatory properties (Merino et al., 2011; Wong et al., 2011; Zawada et al., 2011; Ziegler-Heitbrock et al., 2010) .
Therefore the inflammatory response is fine-tuned depending on activation of specific monocyte subsets. Recent evidence demonstrates monocytes in blood expressing CD14, CD16 and CCR2, unlike classical or non-classical monocytes, have roles in mediating HIV migration across the blood brain barrier and in increasing the severity of TB and cardiovascular disease (Balboa et al., 2011; Buckner et al., 2011; Lentz et al., 2011; Williams et al., 2012; Ziegler-Heitbrock et al., 2010) . These proinflammatory roles are combined with increased antigen presentation in pleural effusions for TB, improved parasite inhibition, and increased MHC class II and accessory molecules in donor gene expression studies (Balboa et al., 2011; Chimma et al., 2009; Wong et al., 2011; Zawada et al., 2011) . Moreover, it has been demonstrated that CD14, CD16, CCR2 expressing monocytes are senescent monocytes, with shortened telomeres and increased chemokine receptor expression, which may characterise increased inflammatory disease in the elderly including disposition to cardiovascular disease (Merino et al., 2011) .
HHV-6 encodes a specific chemokine, U83 which can mediate chemoattraction for latent infection and dissemination in monocytes, but specificity and activity in subsets is not defined. HHV-6B U83B, like the human chemokine CCL2 (formerly monocyte chemotactic protein-1, MCP-1), is monospecific for CCR2, a chemokine receptor expressed on monocytes (Luttichau et al., 2003) . Therefore U83B can both chemoattract cellular populations for establishing latency yet also compete with CCL2 for chemokine receptor activation, thereby diverting the host's cellular responses. This specificity is in contrast to properties of homologous chemokine U83A, encoded by HHV-6A. The U83A chemokine has broad chemokine receptor specificity: CCR1, CCR4, CCR5, CCR6 and CCR8, yet does not include CCR2 (Catusse et al., 2007; Dewin et al., 2006) . The properties of CCL2 have been shown to be essential in a number of systems, including HIV, where it is critical for mediating monocyte movement across the blood brain barrier and for subsequent correlates to neuroinflammatory disease (Buckner et al., 2011; Lentz et al., 2011; Williams et al., 2012) .
During this infiltration, cells mature and become susceptible to HIV infection. HHV-6B is linked with status epilepticus and subsequent temporal lope epilepsy (Epstein et al., 2012) , where there is evidence for a role for CCL2-CCR2 signaling (van Gassen et al., 2008) . Therefore, we hypothesize that monocytes which express CCR2 together with CD14 and possibly CD16 are targets for HHV-6B, with U83B a key candidate for this selectivity. In this report the specificity of this chemokine is addressed and the effects on ex vivo human leukocytes examined. In contrast, U83A is specific for chemokine receptors, CCR5 or CCR6, which are present on dendritic cells and may affect antigen presentation by different pathways. Experiments with a spliced version of U83A, which encodes a truncated version of U83A, U83A-N, show the chemokine binding specificity is retained in the N-terminal half of the molecule (Catusse et al., 2007; Dewin et al., 2006) . Here this is further explored by analysing strain variants in order to define U83B specificity for CCR2. Based on this variation, synthesized peptides covering U83B-N are described to test specificity and activities in mediating migration, using ex vivo human leukocytes to test possible effects on inflammation. Specificity is defined as well as monocyte subset activation. Since chemoattraction of cellular subsets can be a precursor to latent or lytic infection, this specificity difference also defines a putative determinant of cellular tropism differences between HHV-6A and B.
U83B-NT induces chemotaxis in ex vivo CCR2 positive human leukocytes U83B-NT, U83A-NT and U83BA-NT were measured for functional activity using a chemotaxis assay in comparison to human chemokines, in physiological ranges between 0.1-10nM. Chemotaxis was first tested in both a human monocyte cell line, THP-1, which expresses CCR2 to establish the assay ( Fig. 2A) . Then chemotaxis assays were conducted on ex vivo human leukocytes expressing CCR2, derived from multiple independent healthy donors and the combined results analysed (Fig. 2B ). CCR2 and CCR5 specific chemokines, CCL2 and CCL4 respectively, were used as controls. Both CCL2, 10nM positive control, and U83B-NT, 1-100nM, induced chemotaxis in the CCR2 expressing THP-1 cell line ( Fig. 2A ), similar to that reported for a mature U83B-Fc fusion protein (Zou et al., 1999) . In the ex vivo human PBMCs, maximal migration was similar for CCL2 and U83B-NT; significant migration was induced by U83B-NT between 0.1-10nM, with a bell shaped response curve to dilution gradients typical of chemokines. In contrast, stimulation with either U83A-NT or U83BA-NT did not induce chemotaxis of ex vivo PBMC which had showed positive migration to the CCL2 control (Fig. 2C) . No chemotaxis was observed with U83A-NT, U83BA-NT or U83B-NT when donor cells had levels of CCR2 or CCR5 surface expression which were undetectable by flow cytometry and no response to positive control chemokines CCL2 or CCL4, specific for CCR2 or CCR5, respectively (Fig. 2D) . Efficient chemotaxis by U83B-NT but not by U83A-NT or U83BA-NT, shows specificity for CCR2 by U83B resides in this N-terminal region and defines Asn-14 as a key component. Full-length purified, mature U83B effectively displaced radiolabeled CCL2 from binding to CCR2, with an EC50 of 79nM, compared to IC50 of 0.08nM for CCL2 (Luttichau et al., 2003) . In chemotaxis assays, mature U83B, vCCL4, was similarly efficient as CCL2 in promoting migration of CCR2 transfected murine L1.2 cell lines, albeit at higher concentrations of 100-1000nM, compared to effective concentrations for CCL2 of 0.1-10nM (Luttichau et al., 2003) . U83B-NT could not displace CCL2, up to 100nM (not shown) suggesting interactions at a distinct site, while the chemotaxis mediated by U83B-NT was as potent as that induced by the human chemokine CCL2, at 0.1nM-10nM. This suggests signalling is modulated by conformation of the mature virus chemokine and exposure of the U83B N-terminal peptide is important for potency. Human chemokines which bind CCR2 or CCR5 can induce rapid internalisation of the receptor within minutes (Arai et al., 1997; Catusse et al., 2007; Signoret et al., 2005) . The effects of CCL2 and U83B-NT were compared (Fig. 3) . Although CCL2 induced some reduction in surface CCR2 staining, indicative of internalisation of CCR2 as described (Arai et al., 1997) (Fig. 3A, B) , there was no effect by U83B-NT by 10 minutes (Fig. 3C , D, in duplicate at 50nM and in quadruplicate at 1, 5, 10 and 10nM). This resembles effects of U83A on CCR5, which also induces efficient chemotaxis, but with a similar delayed receptor internalisation different from the rapid internalisation/recycling induced by human chemokines (Catusse et al., 2009; Catusse et al., 2007) . Interestingly, CCL2 induced chemotaxis has also been reported independent of CCR2 internalisation (Arai et al., 1997) .
The mature U83B, is monospecific for CCR2 and shows no interaction with CCR5 or other human chemokine receptors including CX3CR1 (Luttichau et al., 2003) . This suggests specificity for classical or intermediate monocytes. In the chemotaxis assay donor PBMC bearing CCR2 could be specifically stimulated by U83B-NT (and also CCL2) and positive chemotaxis could only be observed in donors where there was a relatively high overall prevalence of CCR2 bearing cells in the PBMC population. In order to further investigate this specificity, the phenotype of the actual migrated population of ex vivo PBMC was characterised. Since this assay actually phenotypes the migrated population, it could be performed on donor PBMC in which the relative prevalence of CCR2+ leukocytes in the starting population from donor PBMC was lower or even a minor group. The chemotaxed cells were collected and examined by flow cytometry. expression, as shown previously (Catusse et al., 2009; Catusse et al., 2007) , treatment with U83B-NT did not increase migration of CCR5 bearing PBMCs. In contrast, there was enrichment of CCR5, but not CCR2, bearing cells after migration towards full length mature U83A ( Fig. 4D ), which has specificity for CCR5, but not CCR2 (Catusse et al., 2007; Dewin et al., 2006) . Since the migration of CCR2 and not CCR5 bearing PBMCs was increased with U83B-NT relative to the buffer-only treatment, this indicates CCR2 specificity rather than general leukocyte activation. 
Shape change assay for cellular activation induced by U83B peptide
Shape change is an indicator of cellular activation and can involve alterations in cell size, granularity or overall morphology as shown for CCL4 and U83A treatment of CCR5 expressing human leukocytes by confocal microscopy and on eosinophils treated with CCL11 by flow cytometry (Catusse et al., 2007; Sabroe et al., 1999; Signoret et al., 2005) . CCR5 cells interacting with CCL4 show internalisation of CCR5 and a decreased cellular morphology, whereas CCR3 expressing eosinophils treated with cognate ligand CCL11 react with morphological changes leading to increased forward scatter in flow cytometry. A similar flow cytometry based assay was established using ex vivo PBMCs to further investigate the the CCR2 specificity of U83B-NT activation, and the affected monocyte subsets (Fig. 5 ).
Shape change in response to chemokine stimulation was first compared between CCR2 and CCR5 expressing cells using gating strategy is shown in Fig. 5A -D. PBMCs were stimulated with chemokine or buffer only treatment control then either CCR2 or CCR5 expressing cells gated on (Fig. 5A , B) and CD3 expressing and/or dead cells gated out (lineage gating, Fig.   5C , D). Chemokine stimulated changes in forward scatter, either increased for CCR2 or decreased for CCR5, were then analysed as compared to no treatment buffer only control (Fig. 5E ).
The effects of U83B-NT were compared with those induced by stimulation with human chemokines specific for CCR2 or CCR5, CCL2 or CCL4 respectively, in relation to buffer only treatment (Fig. 5E ). Both CCL2 and U83B-NT showed similar shape change effects in increasing forward scatter relative to the buffer control in the CCR2+/CD3-population (Fig.   5E ). In contrast, CCL4 stimulation had little effect on these CCR2+/CD3-cells, while in the CCR5+/CD3-cells, CCL4 stimulation resulted in a decrease in forward scatter, consistent with alterations in cellular morphology previously observed. There was no effect on CCR5+/CD3-PMBCs of either CCL2 or U83B-NT. This further shows the specificity of the effect of U83B-NT in activating CCR2+ PBMCs. Monocytes are a major population expressing CCR2. T-lymphocyte subsets may also express CCR2, but since CD3 expressing cells were also gated out here, it is likely that monocytes are the main population responding.
Although NK or dendritic cells may also be present, these generally express CCR5 in activated forms. CCR2+/CD3-cells and CCR5+/CD3-cells which changed shape (increase or decrease in forward scatter profile, respectively) relative to the buffer median were assessed by flow cytometry to enable the frequency of CD14+, CD16+ populations in the increased (CCR2+CD3-) or decreased (CCR5+CD3-) forward scatter gates to be compared between chemokine and buffer only treatments (Fig. 5E ). Both the U83A-NT and negative control human chemokine CCL4 (CCR5 specific) stimulation of CCR2+CD3-cells, showed no difference to the buffer-only treatment ( Fig. 5E Intermediate monocytes and non-classical monocytes, which express both CD14 and CD16, have been increasingly defined as an intrinsic subset for virus interactions and some other intracellular pathogens (Balboa et al., 2011; Buckner et al., 2011; Chimma et al., 2009; Lentz et al., 2011; Williams et al., 2012) . With lower expression of CD14, human CD14dim monocytes have roles in local tissue surveillance to detect nucleic acids and viruses via innate The CCR2+CD14+CD16+ phenotype has also been characterised as increased in senescent cells, and can explain the increase in chronic inflammatory conditions in ageing populations including those with cardiovascular disease (Merino et al., 2011; Rogacev et al., 2011; Shantsila et al., 2011) . HHV-6B is associated with inflammatory conditions, including encephalitis and myocarditis, where it is the most frequent virus identified together with parvovirus 19 (Kuhl et al., 2005a) . Therefore, the U83B specificity further defined here, provide a mechanism for modulation of the inflammatory response.
Since both HHV-6A and HHV-6B have also recently been identified as integrated genomes ranging between 0.1 -1.0% of global populations, up to 70 million people are potentially exposed to effects of these virus genes (Arbuckle et al., 2010; Arbuckle & Medveczky, 2011; Morissette & Flamand, 2010) . Evidence suggests the integrated HHV-6 is primarily in a latent state, but there are reports of reactivation giving placental infection (Hall et al., 2010) .
Moreover, in the absence of other virus gene expression both HHV-6A and HHV-6B U83-N, can be expressed, encoding the spliced truncated version which includes the U83B peptide (French et al., 1999) . This immediate early profile suggests U83 is competent to be expressed from the genome, could be expressed from every cell, thereby enhancing chemokine activities in addition to CCL2 in inflammatory disorders. Notably, CCL2 has been described in both neuroinflammatory and cardiovascular pathologies and U83B with similar properties, but potentially wider cellular distribution as an integrated gene could contribute to this. (MIP-1β) and CCL5 (RANTES) were purchased in lyophilized form from Peprotech (Rocky Hill, NJ, USA) and reconstituted according to the manufacturer's instructions. 10mM aliquots of the chemokines were prepared, diluting the reconstituted peptide in Phosphate Buffered Saline (PBS), pH8. These aliquots were stored at -80°C. Working stocks (10μM) were prepared when required from these aliquots in HEPES buffered saline solution (HBSS, Sigma) with 0.1% bovine serum albumin (BSA, Sigma) and were stored at -20°C. Working stocks were discarded after two freeze-thaw cycles. Viral chemokine peptides were synthesised by Sigma-Genosys and reconstituted using the manufacturer's instructions.
Briefly, chemokine was reconstituted with DMSO (Sigma) to make a 5mM stock concentration and then aliquots of 100μM and 10μM prepared using PBS/0.1% BSA and stored at -20°C. After two freeze-thaw cycles aliquots were discarded.
Polymerase chain reaction (PCR) amplification and nucleotide sequencing. HHV-6 DNA was isolated from infant sera samples collected in Zambia as part of analyses of infection effects in a nutrition intervention study as described (CIGNISstudyteam, 2010) . HHV-6 U83 was PCR amplified using Gotaq green mastermix (Promega) or Pfu polymerase (New England Biosciences), as described (Bates et al., 2009; French et al., 1999) . Outer primers U83OF/OR were used followed by a nested set, U83IF/IR: U83OF 5'AGTTAACACGACGGGAACAAC3', U83OR 5'TTGGGATGATTATGGCAAACT3', U83IF 5'GTAGGGAAAAAGACTTGTCGAA3', U83IR
5'AACCAGTATTAATGTCTTCGA3'. Gel purified DNA PCR products were sequenced using Big dye terminator 3.1 (Applied Biosystems) and run on an ABI3730 (Applied Biosystems). Sequences were analysed using Chromas pro (Technelysium) and compared to chemokine sequences on Genbank using NCBI BLAST. Alignments were prepared using ClustalW (Chenna et al., 2003) and Jalview v2.4 (Waterhouse et al., 2009) . Whole blood was collected with 5mM EDTA (final concentration) from anonymously coded healthy adult human blood donors (LSTHM, UK), with written consent, following local phlebotomy guidelines. PBMCs were separated from whole blood using Histopaque-1077 (Sigma). PBMCs for culture were resuspended in RPMI-1640 with 10% autologous human serum, 2mM Glutamax (Fisher), 50 U/mL penicillin (Sigma), 50 μg/mL streptomycin (Sigma), plated in an ultra-low adherence flask (Corning, Corning, NY) and incubated at 37 o C with 5% CO 2 for 72h as described (Catusse et al., 2007) .
Chemotaxis assay.
PBMCs at a density of 2x10 6 /ml were incubated in HBSS with 0.1% BSA and 1.7μM Calcein-AM (Invitrogen) for 30 minutes at 37°C, 5% CO 2 . Cells were washed in chemotaxis buffer (HBSS/0.1% BSA), then 1.5x10 5 cells, at a density of 3x10 6 /ml, were plated out on a Neuroprobe ChemoTX™ microchemotaxis chamber (Receptor Technologies, UK) on the filter above the lower chambers containing chemokine, peptide or buffer. The assay was then run for 90 minutes by incubation of the cell and chemokine/peptide filled microchemotaxis chamber at 37°C, 5% CO 2 . Excess cells were removed from the filter and cells migrated into the lower chamber were assayed using calcein fluorescence measured with a Wallac Victor2 spectrometer (Perkin Elmer) with excitation 485nm and emission 535nm as described (Catusse et al., 2007) . Cells were stimulated with human chemokines, CCR2 specific CCL2 or CCR5 specific CCL4, virus chemokine U83B-NT or buffer for 90 minutes and then stained for cell markers.
In this assay cells were stained for: CCR2 (PE, for gating CCR2 expressing cells), CCR5
(FITC, for gating in CCR5 expressing cells), CD3 (pacific blue, PB, for gating out T cells), Dead cell stain (PB analogue, for gating out dead cells), CD14 (APC, For gating monocytic cells), CD16 (PE-Cy7, for gating cells bearing this Fc receptor). In order to define chemokine specific responses to chemokine receptors on the cell surface, cell populations were first defined by chemokine receptor expression, either CCR2 or CCR5, which were gated in separately to be able to compare their responses. Next the CD3+/dead cells were gated out. Finally, the shape change effect on chemokine stimulated cells was evaluated by changes in forward scatter relative to the no treatment buffer only control. 10nM, CCL4 10nM, or buffer only. In the left panels cells expressing CCR2 respond to specific chemokine stimulation by increases in forward scatter, a larger, more granular morphology, as shown for both CCL2 and U83B-NT stimulation relative to the buffer. In the right panels cells expressing CCR5 respond only to specific chemokine CCL4 stimulation showed by decreases in forward scatter, acquisition of a smaller, less granular morphology, relative to buffer. Cells were then gated (black arrows) on the increased or decreased forward scatter profiles relative to the buffer control histogram median and the relative prevalence of CD14 or CD16 cell surface marker in the shape-changed population was further determined (Table 1) . 
